Business
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that
About this update from Urogen Pharma Ltd.
[{"type":"text","content":" PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial utilization review of JELMYTO® (mitomycin) for pyelocalyceal solution. This is the first study to compare modes of administration for JELMYTO, an approved treatment for low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Findings from the study titled, Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes, are published in the European Urology Focus online.\n\n\nIn this sub-analysis, 136 renal units were treated in 132 patients (43% via antegrade and 57% via retrograde) with at least one dose of JELMYTO. Investigators reported that the overall rate of stricture occurrence was lower with the antegrade approach (12%) compared to retrograde group (32%). Although no significant difference in response was observed, the antegrade group showed a higher complete response (CR) rate of 60% compared to 48% in the retrograde group (p=0.1). Partial response (PR) rates were also favorable, with 60% CR and 32% PR for antegrade administration, and 48% CR and 28% PR for retrograde administration. In this study, survival outcomes are reported per patient and treatment, complications and recurrence outcomes are reported per renal unit.\n\n\nIn the OLYMPUS clinical study, data were generated for the retrograde administration of JELMYTO. In that study population, ureteric obstruction was reported in 58% (n=41) of patients receiving JELMYTO, including 17% (n=12) of patients who experienced Grade 3 obstruction.\n\n\n“These results are encouraging because they add to recent evidence that suggests the antegrade mode of administration of JELMYTO may have potential advantages,” said Jennifer Linehan, M.D., Associate Professor of Urology and Urologic Oncology, St. Joseph’s Cancer Institute, Providence Specialty Medical Group, Santa Monica, CA. “Since JELMYTO was approved for both retrograde and antegrade administration, physicians and patients should have more confidence in choosing antegrade when evaluating the pros and cons of each treatment approach.”\n\n\nMark Schoenberg, M.D., Chief Medical Officer, UroGen, shared similar sentiments, ...